New-Generation Drug-Eluting Stents: Focus on Xience V® Everolimus-Eluting Stent and Resolute® Zotarolimus-Eluting Stent

Compared to bare metal stent angioplasty, first-generation drug-eluting stents (DES) have markedly reduced the incidence of in-stent restenosis. However, given the increased concerns over late and very late stent thrombosis, newer-generation DES were developed. To date, these DES have virtually replaced the use of first-generation DES worldwide. In this review article, we carefully consider the pre-clinical and clinical trials that have been performed with currently available, european conformity-marked and Food and Drug Administration-approved new-generation Resolute (R) and Xience V (R) DES. (J Interven Cardiol 2013;26:278-286)